På Placera och Avanza använder vi cookies för att säkerställa funktionalitet, personalisera innehåll och annonser och för att analysera hur sajten används. Genom att godkänna accepterar du att cookies används. Läs mer och hantera inställningar

BB Biotech: Sharp dip in premium - SEB (SEB Research)

2022-08-11 14:52

Along with the rest of the Biotech sector, BB Biotech had a rough first half of 2022: the fund has reported a H1 loss of CHF 533mm, a sharp reversal from H1 2021. However, we agree with BB that the biotech sell-off is overdone and that the sector is undervalued, which presents it with attractive investment opportunities. The fund is trading at a premium of only 14.5%, in line with its historical norm.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.


redaktion@finwire.org
© Copyright

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -